Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 11:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 146 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: 1000 mg metformin Clear all
Completed Phase 2 Interventional Results available

Metformin for Preventing Frailty in High-risk Older Adults

NCT02570672
View directory record Official record
Conditions
Frailty
Interventions
Metformin, Placebo
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
65 Years to 90 Years
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 6, 2025 · Synced Oct 7, 2026, 11:46 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-drug Interaction Study With Metformin and Imatinib

NCT01404715
View directory record Official record
Conditions
Healthy
Interventions
Metformin, Imatinib
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 45 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 10, 2014 · Synced Oct 7, 2026, 11:46 PM EDT
Completed Phase 3 Interventional Results available

EMERALD: Effects of Metformin on Cardiovascular Function in Adolescents With Type 1 Diabetes

NCT01808690
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Metformin, Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
12 Years to 21 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 30, 2021 · Synced Oct 7, 2026, 11:46 PM EDT
Completed Phase 1 Interventional

Single Cohort, 2-Period Study to Assess Pharmacokinetics of Metformin Alone and in Combination With Ranolazine 500 mg

NCT01546558
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Metformin, Ranolazine
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
30 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 11, 2012 · Synced Oct 7, 2026, 11:46 PM EDT
Completed Phase 3 Interventional Results available

A Study Assessing Saxagliptin Treatment in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise

NCT00374907
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Saxagliptin, Placebo, Metformin (blinded), Metformin (open-label)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
3
States / cities
San Diego, California • Baton Rouge, Louisiana • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 7, 2015 · Synced Oct 7, 2026, 11:46 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Bioequivalence Study of 500 mg and 1000 mg Glucophage (Metformin) Tablets in Healthy Subjects

NCT01068730
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
metformin (Diabex), metformin (Glucophage™)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 8, 2015 · Synced Oct 7, 2026, 11:46 PM EDT
Completed Phase 2 Interventional Results available

Feasibility Study of Metformin Therapy in ADPKD

NCT02903511
View directory record Official record
Conditions
Polycystic Kidney, Autosomal Dominant
Interventions
Metformin, Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
30 Years to 60 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 5, 2021 · Synced Oct 7, 2026, 11:46 PM EDT
Active, not recruiting Phase 2 Interventional

Glycemic Regulation as Endometriosis Adjunct Treatment

NCT06611501
View directory record Official record
Conditions
Pelvic Pain, Endometriosis
Interventions
Metformin Hydrochloride, Placebo
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
15 Years to 35 Years · Female only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 7, 2026, 11:46 PM EDT
Completed Phase 3 Interventional

Study of the Safety and Tolerability of Switching to ITCA 650 in Patients With Type 2 Diabetes Receiving Liraglutide

NCT02638805
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
ITCA 650 Osmotic Mini Pump 20/60 mcg/day, ITCA 650 Osmotic Mini Pump 60 mcg/day, Metformin, Liraglutide
Drug
Lead sponsor
Intarcia Therapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
36
States / cities
Birmingham, Alabama • Gulf Shores, Alabama • Little Rock, Arkansas + 28 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2018 · Synced Oct 7, 2026, 11:46 PM EDT
Completed Phase 3 Interventional Results available

Effect of Detemir and Sitagliptin on Blood Glucose Control in Type 2 Diabetes

NCT00789191
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin detemir, sitagliptin, metformin, sulphonylurea
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
10
States / cities
Vestavia Hills, Alabama • Orange, California • Santa Monica, California + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2017 · Synced Oct 7, 2026, 11:46 PM EDT
Completed Phase 3 Interventional Results available

Adjunctive Metformin Therapy in Double Diabetes

NCT01334125
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Metformin, Placebo
Drug
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
10 Years to 20 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 4, 2016 · Synced Oct 7, 2026, 11:46 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Combined Liraglutide and Metformin Therapy in Women With Previous Gestational Diabetes Mellitus (GDM)

NCT01234649
View directory record Official record
Conditions
Gestational Diabetes Mellitus, Type 2 Diabetes Mellitus, Metabolic Syndrome, Impaired Glucose Tolerance, Disorder of Glucose Regulation
Interventions
Metformin XR plus placebo, Metformin XR plus liraglutide
Drug
Lead sponsor
Woman's
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
153 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2019
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Jul 26, 2019 · Synced Oct 7, 2026, 11:46 PM EDT
Completed Not applicable Interventional Results available

A Pilot Study: Metformin Therapy in Heart Failure Patients With Early Diabetes or at High Risk of Developing Diabetes (Pre-Diabetes)

NCT01573949
View directory record Official record
Conditions
Diabetes, Heart Failure
Interventions
Metformin
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 90 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 4, 2020 · Synced Oct 7, 2026, 11:46 PM EDT
Completed Phase 4 Interventional Results available

Efficacy and Safety of Switching From Sitagliptin to Liraglutide in Subjects With Type 2 Diabetes Not Achieving Adequate Glycaemic Control on Sitagliptin and Metformin

NCT01907854
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
liraglutide, sitagliptin, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
407 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
58
States / cities
Phoenix, Arizona • Tucson, Arizona • Escondido, California + 46 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2018 · Synced Oct 7, 2026, 11:46 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I Study to Assess the Pharmacokinetics of Metformin When Administered Alone and in Combination With Vandetanib

NCT01551615
View directory record Official record
Conditions
Healthy
Interventions
Metformin 1000 mg, Vandetanib 800 mg
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 50 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 29, 2016 · Synced Oct 7, 2026, 11:46 PM EDT
Completed Phase 4 Interventional Results available

Ranolazine and Microvascular Angina by PET in the Emergency Department

NCT02052011
View directory record Official record
Conditions
Microvascular Angina
Interventions
Ranolazine, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
30 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 16, 2017 · Synced Oct 7, 2026, 11:46 PM EDT
Completed Phase 3 Interventional Results available

ACTIV-6: COVID-19 Study of Repurposed Medications

NCT04885530
View directory record Official record
Conditions
Covid19
Interventions
Ivermectin, Fluvoxamine, Fluticasone, Placebo, Montelukast, Metformin
Drug · Other
Lead sponsor
Susanna Naggie, MD
Other
Eligibility
30 Years and older
Enrollment
10,956 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
110
States / cities
Chandler, Arizona • Gilbert, Arizona • Mesa, Arizona + 96 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2025 · Synced Oct 7, 2026, 11:46 PM EDT
Completed Phase 1Phase 2 Interventional

Gemcitabine+Nab-paclitaxel and FOLFIRINOX and Molecular Profiling for Patients With Advanced Pancreatic Cancer

NCT01488552
View directory record Official record
Conditions
Stage IV Pancreatic Cancer
Interventions
Gemcitabine, nab-paclitaxel, FOLFIRINOX, Immunohistochemistry (IHC) Analysis, Metformin, mFOLFIRI
Drug · Genetic
Lead sponsor
Pancreatic Cancer Research Team
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
5
States / cities
Scottsdale, Arizona • Burbank, California • Minneapolis, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2016 · Synced Oct 7, 2026, 11:46 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Study of Clinical Response to Acute Metformin By Leveraging Evaluations During a Mixed Meal Tolerance Test for Exploring Glycemia and GeneticS

NCT02087826
View directory record Official record
Conditions
Genetics, Metabolism, Type 2 Diabetes
Interventions
Mixed Meal Tolerance Test, Metformin
Other · Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 79 Years
Enrollment
1,017 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 15, 2026 · Synced Oct 7, 2026, 11:46 PM EDT
Completed Phase 2 Interventional

Efficacy and Safety of Metformin and Liraglutide in Obese Subjects With Type 2 Diabetes Previously Treated With an Oral Hypoglycemic Agent

NCT01511198
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
liraglutide, metformin
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 75 Years
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001
U.S. locations
39
States / cities
Vestavia Hills, Alabama • Tucson, Arizona • Carlisle, Arkansas + 32 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2017 · Synced Oct 7, 2026, 11:46 PM EDT
Completed Phase 2 Interventional

Safety and Feasibility of Metformin for Sepsis Induced AKI

NCT05900284
View directory record Official record
Conditions
Sepsis, Septic Shock, Acute Kidney Injury, Metformin
Interventions
Metformin low dose, Metformin high dose, Placebo
Drug
Lead sponsor
Hernando Gomez
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 7, 2026, 11:46 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Title: Therapeutic Targets in African-American Youth With Type 2 Diabetes

NCT02960659
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Liraglutide, Metformin
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
12 Years to 25 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 1, 2023 · Synced Oct 7, 2026, 11:46 PM EDT
Completed Phase 1 Interventional

Study to Evaluate the Bioequivalence of a Test Tablet Formulation of Metformin HCl (1000 mg), Compared to an Equivalent Dose of a Commercially Available Reference Drug Product (Glucophage®, Bristol-Myers Squibb Company) in Fed, Healthy, Adult Subjects

NCT00944346
View directory record Official record
Conditions
Healthy
Interventions
Metformin HCl
Drug
Lead sponsor
Torrent Pharmaceuticals Limited
Industry
Eligibility
18 Years and older
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 23, 2009 · Synced Oct 7, 2026, 11:46 PM EDT
Completed Phase 1 Interventional

Study to Evaluate the Bioequivalence of a Test Tablet Formulation of Metformin HCl (1000 mg), Compared to an Equivalent Dose of a Commercially Available Reference Drug Product (Glucophage®, Bristol-Myers Squibb Company) in Fasted, Healthy, Adult Subjects

NCT00944177
View directory record Official record
Conditions
Healthy
Interventions
Metformin HCl
Drug
Lead sponsor
Torrent Pharmaceuticals Limited
Industry
Eligibility
18 Years and older
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 23, 2009 · Synced Oct 7, 2026, 11:46 PM EDT